Orphan drug designation provides benefits such as tax credits, PDUFA fee waivers, and 7 years of market exclusivity upon ...
The U.S. Food and Drug Administration has granted orphan drug designation to the investigational therapy MNV-201 for patients with myelodysplastic syndrome, a serious, age-related blood disorder that ...
Myelodysplastic syndromes (MDS) and autoimmune conditions appear to have a two-way connection. Living with one may increase your risk of developing the other. Myelodysplastic syndromes (MDS) are a ...
Five people living with myelodysplastic syndromes (MDS) or in survivorship talk about their experiences with this serious and commonly misunderstood group of conditions. Myelodysplastic syndromes (MDS ...
Robin Roberts, the beloved host of "Good Morning America," recently visited New Albany to speak at the New Albany ...
More than half of patients with high-risk myelodysplastic syndrome may not be receiving guideline-recommended treatment with ...
April 30, 2010 — Myelodysplastic syndromes (MDS) appear to be nearly 5 times more common in older adults than previously thought, according to a new study published online April 26 in the Journal of ...
DelveInsight's " Myelodysplastic Syndrome with Excess Blasts2 Market Insight, Epidemiology And Market Forecast - 2032 " report provides an in-depth understanding of the Myelodysplastic Syndrome with ...
IDH1 mutations in MDS are crucial for guiding therapy decisions, offering one of the few targetable mutations in this disease ...
Racial disparities are known to occur with many diseases, including numerous cancers, with Black individuals having lower survival rates than other racial/ethnic groups. However, there have not been ...
Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell TherapyHAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback